国药集团一致药业股份有限公司 2016 年第一季度报告全文
China National Accord Medicines Corporation Ltd.
First Quarterly Report 2016
April 2016
1
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Section I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord
Medicines Corporation Ltd. (hereinafter referred to as the Company) and its
directors, supervisors and senior executives should guarantee the reality,
accuracy and completion of the quarterly report, there are no any fictitious
statements, misleading statements or important omissions carried in this report,
and shall take legal responsibilities, individual and/or joint.
All Directors are attended the Board Meeting for Quarterly Report deliberation.
Lin Zhaoxiong person in charge of the Company, Wei Pingxiao, person in
charger of accounting works and Wang Ying, person in charger of accounting
organ (accounting officer) hereby confirm that the Financial Report of this
Quarterly Report is authentic, accurate and complete.
2
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Section II. Main financial data and changes of shareholders
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting
error correction or not
□ Yes √No
Changes of this period over
Current Period Same period of last year
same period of last year
Operating income (RMB) 7,053,846,519.17 6,261,714,700.23 12.65%
Net profit attributable to shareholders of
199,027,472.31 197,026,237.82 1.02%
the listed company(RMB)
Net profit attributable to shareholders of
the listed company after deducting 187,445,696.09 192,315,542.07 -2.53%
non-recurring gains and losses(RMB)
Net cash flow arising from operating
-100,461,465.99 182,179,606.70 -155.14%
activities(RMB)
Basic earnings per share (RMB/Share) 0.549 0.543 1.10%
Diluted earnings per share (RMB/Share) 0.549 0.543 1.10%
Weighted average ROE 3.58% 4.05% -0.47%
Changes of this period-end
At the end of the reporting
At the end of last year over same period-end of last
period
year
Total assets (RMB) 14,172,328,814.96 13,218,349,735.31 7.22%
Net assets attributable to shareholder of
5,652,382,580.33 5,453,393,694.55 3.65%
listed company (RMB)
Items of non-recurring gains and losses
√ Applicable □ Not applicable
In RMB
Amount from year-begin to
Item Note
period-end
Mainly because the subsidiary
Gains/losses from the disposal of non-current asset (including the Guangxi Logistics disposed the
9,117,952.96
write-off that accrued for impairment of assets) house property and obtained
compensation for demolition;
Governmental subsidy reckoned into current gains/losses (not
Mainly due to the various special
including the subsidy enjoyed in quota or ration according to
4,043,684.40 grants received in the current
national standards, which are closely relevant to enterprise’s
period;
business)
3
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Mainly because the bad debts of
Reversal of impairment reserve for account receivable with receivables withdrawn alone in
953,105.02
separate impairment testing the previous years have been
taken back in the current period;
Other non-operating income and expenditure except for the
1,110,983.48
aforementioned items
Less: impact on income tax 3,514,045.71
Impact on minority shareholders’ equity (post-tax) 129,903.93
Total 11,581,776.22 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss
II. Total number of shareholders at the end of this report period and top ten shareholders
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In shares
Total preference shareholders
Total common shareholders
with voting rights recovered at
16,413 0
at the end of report period end of reporting period (if
applicable)
Top ten shareholders
Amount of Number of share pledged/frozen
Shareholder’s Nature of Proportion of Amount of shares
restricted shares
name shareholder shares held held State of share Amount
held
Sinopharm Group State-owned legal
51.00% 184,942,291 74,482,543
Co., Ltd. person
National Social Domestic non
Security Fund state-owned legal 2.01% 7,298,555
106 combination person
Domestic non
China Securities
state-owned 1.97% 7,132,757
Finance Co., Ltd.
Corporation
HTHK/CMG
FSGUFP-CMG Foreign
1.94% 7,032,720
FIRST STATE Corporation
CHINA
4
国药集团一致药业股份有限公司 2016 年第一季度报告全文
GROWTH FD
VALUE
Foreign
PARTNERS 1.42% 5,138,568
Corporation
CLASSIC FUND
Domestic non
CITIC Securities
state-owned 1.38% 5,008,637
Co., Ltd.
Corporation
National Social Domestic non
Security Fund state-owned legal 1.32% 4,783,965
116 combination person
New China Life
Insurance Co.,
Ltd. – Bonus – Domestic non
Individual state-owned 1.16% 4,199,772
bonuses - Corporation
-018L-FH002
Shen
Central Huijin State-owned
1.05% 3,804,400
Investment Ltd. Corporation
China Life
Insurance Co.,
Ltd. – tradition – Domestic non
general insurance state-owned 1.03% 3,750,090
products - Corporation
005L-CT001
Shen
Top ten shareholders with unrestricted shares held
Type of shares
Shareholder’s name Amount of unrestricted shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 110,459,748 110,459,748
shares
National Social Security Fund 106 RMB ordinary
7,298,555 7,298,555
combination shares
RMB ordinary
China Securities Finance Co., Ltd. 7,132,757 7,132,757
shares
Domestically
HTHK/CMG FSGUFP-CMG FIRST
7,032,720 listed foreign 7,032,720
STATE CHINA GROWTH FD
shares
Domestically
VALUE PARTNERS CLASSIC
5,138,568 listed foreign 5,138,568
FUND
shares
5
国药集团一致药业股份有限公司 2016 年第一季度报告全文
RMB ordinary
CITIC Securities Co., Ltd. 5,008,637 5,008,637
shares
National Social Security Fund 116 RMB ordinary
4,783,965 4,783,965
combination shares
New China Life Insurance Co., Ltd.
RMB ordinary
– Bonus – Individual bonuses - 4,199,772 4,199,772
shares
-018L-FH002 Shen
RMB ordinary
Central Huijin Investment Ltd. 3,804,400 3,804,400
shares
China Life Insurance Co., Ltd. –
RMB ordinary
tradition – general insurance 3,750,090 3,750,090
shares
products - 005L-CT001 Shen
Explanation on associated It is unknown that there exists no associated relationship or belongs to the consistent actionist
relationship among the aforesaid among the above shareholders regulated by the Management Measure of Information
shareholders Disclosure on Change of Shareholding for Listed Companies.
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The top ten common shareholders or top ten common shareholders with un-restrict shares held of the Company have no buy-back
agreement dealing in reporting period.
2. Total shareholders with preferred stock held at Period-end and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
6
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Section III. Significant Events
I. Particulars about material changes in items of main accounting statement and financial
index and explanations of reasons
√Applicable □Not applicable
1. Divided into assets held for sale: a decrease of 2,456,900 yuan compared with the beginning of the period, with a growth rate of
-100.00%, mainly because the underlying assets have been completed in the current transaction;
2. Other current assets: a decrease of 7,106,200 yuan compared with the beginning of the period, with a growth rate of -36.52%,
mainly because the value added tax retained has reduced in the current period;
3. Employee pay payable: a decrease of 68,188,800 yuan compared with the beginning of the period, with a growth rate of -41.50%,
mainly because employee remuneration withdrawn in the previous year has been issued in the current period;
4. Taxes payable: an increase of 39,752,200 yuan compared with the beginning of the period, with a growth rate of 54.56%, mainly
due to the sales growth in current period resulting in an increase of provision for income tax;
5. Non-current liabilities due within one year: an increase of 2,075,200 yuan compared with the beginning of the period, with a
growth rate of 38.11%, mainly due to the increase of member points in the current period;
6. Non-operating expenses: a decrease of 151,700 yuan on a year-on-year basis, with a growth rate of -46.84%, mainly because the
loss of non-current assets disposed in the current period has reduced on a year-on-year basis;
7. Tax refunds received: an increase of 3,753,300 yuan on a year-on-year basis, with a growth rate of 1,125.52%, mainly because the
increase of the amount of exports in the last year has led to an increase of amount of export rebates in the current period;
8. Other cash paid relating to operating activities: a decrease of 24,517,900 yuan on a year-on-year basis, with a growth rate of
-30.29%, mainly due to the decrease of cash outflow related to expenses on a year-on-year basis;
9. Net cash flow from operating activities: a decrease of 283 million yuan on a year-on-year basis, with a growth rate of -155.14%,
mainly because the cash paid for the purchase of goods and the service payments has increased on a year-on-year basis;
10. Net cash received by disposing fixed assets, intangible assets and other long-term assets: an increase of 2,126,900 yuan on a
year-on-year basis, with a growth rate of 9,524.51%, mainly due to an increase of fixed assets income disposed in the current period
on a year-on-year basis;
11. Sub-total of cash inflows from investing activities: an increase of 2,126,900 yuan on a year-on-year basis, with a growth rate of
9,524.51%, mainly due to an increase of fixed asset income disposed in the current period on a year-on-year basis;
12. Cash paid for the purchase and construction of fixed assets, intangible assets and other long-term assets: a decrease of 17,563,300
yuan, with a growth rate of -35.57%, mainly due to a decrease in expenditures for acquisition of fixed assets in the current period on
a year-on-year basis;
13. Other cash paid relating to investing activities: an increase of 26,502,400 yuan on a year-on-year basis, with a growth rate of
10,516.81%, mainly because the earnest money for transferring the stock rights of subsidiaries has been returned in the current
period;
14. Cash received by absorbing investments: a decrease of 1.47 million yuan on a year-on-year basis, with a growth rate of -100.00%,
mainly because there were investment funds paid to minority shareholders of subsidiaries at the same period of last year but there is
no such business in the current period;
15. Cash received from debts: an increase of 46,309,900 yuan on a year-on-year basis, mainly due to an increase in bank loans in the
current period on a year-on-year basis;
7
国药集团一致药业股份有限公司 2016 年第一季度报告全文
16. Other cash received relating to financing activities: an increase of 112 million yuan on a year-on-year basis, mainly because the
supply chain financing funds received in the current period have increased on a year-on-year basis;
17. Sub-total of cash inflows from financing activities: an increase of 157 million yuan on a year-on-year basis, with a growth rate of
10,671.16%, mainly because the supply chain financing funds received in the current period have increased on a year-on-year basis;
18. Other cash paid relating to financing activities: a decrease of 27,930,600 yuan on a year-on-year basis, with a growth rate of
-96.27%, mainly because the supply chain financing funds received in the current period have decreased on a year-on-year basis;
19. Net cash flow from financing activities: an increase of 175 million yuan on a year-on-year basis, with a growth rate of 149.72%,
mainly because the supply chain financing funds received in the current period have increased on a year-on-year basis;
20. Effects of exchange rate changes on cash and cash equivalents: a decrease of 9,250.41 yuan on a year-on-year basis, with a
growth rate of -100.00%, mainly due to a decrease in foreign currency holdings on a year-on-year basis.
21. Net increase in cash and cash equivalents: a decrease of 115 million yuan on a year-on-year basis, with a growth rate of -721.18%,
mainly because the net cash flow from operating activities has decreased by 283 million yuan on a year-on-year basis.
II. Analysis and explanation of significant events and their influence and solutions
√Applicable □Not applicable
The company held the 13th meeting of the seventh board of directors on March 9, 2016 which reviewed and
approved the "Proposal on the company’s asset sale, issue of shares and cash purchase of assets and the raise of
matching funds and the program of related transaction", "Proposal on the asset sale, issue of shares and cash
purchase of assets and the raise of matching funds and the related transaction plan of China National Accord
Medicines Corporation Ltd." and other related proposals, and released the announcement about "Asset sale, issue
of shares and cash purchase of assets and the raise of matching funds and the related transaction plan of China
National Accord Medicines Corporation Ltd." on the designated information disclosure media on March 10, 2016.
On March 17, 2016, the company received the "Inquiry letter about the restructuring of China National Accord
Medicines Corporation Ltd." (XKLCZWXH No. [2016] 22) issued by Shenzhen Stock Exchange. The company
has replied the questions involved in the inquiry letter and revised the relevant documents of this major asset
restructuring plan, please see the relevant replies and revision of relevant documents on “Revision announcement
about the asset sale, issue of shares and cash purchase of assets and the raise of matching funds and the related
transaction plan of China National Accord Medicines Corporation Ltd.”, and “Asset sale, issue of shares and cash
purchase of assets and the raise of matching funds and the related transaction plan of China National Accord
Medicines Corporation Ltd.” released on the designated information disclosure media on March 25, 2016.
Since the disclosure of this major asset restructuring plan, the company, transaction parties and engaged
intermediaries are actively promoting the audit, evaluation, and due diligence and other work related to the
restructuring, after the completion of above-mentioned work, the company shall establish the reports and other
documents related to this major asset restructuring, and reconvene the board meeting to consider the relevant
matters involving in this major asset restructuring.
Interim report disclosure website query
Overview of important matters Date of disclosure
index
"Proposal on the asset sale, issue of shares
and cash purchase of assets and the raise of
Juchao Website
matching funds and the related transaction 2016-03-10
(http://www.cninfo.com.cn)
plan of China National Accord Medicines
Corporation Ltd." etc.
8
国药集团一致药业股份有限公司 2016 年第一季度报告全文
“Revision announcement about the asset
sale, issue of shares and cash purchase of
assets and the raise of matching funds and
the related transaction plan of China
National Accord Medicines Corporation Juchao Website
2016-03-25
Ltd.”, and revised “Asset sale, issue of (http://www.cninfo.com.cn)
shares and cash purchase of assets and the
raise of matching funds and the related
transaction plan of China National Accord
Medicines Corporation Ltd.”
III. Commitments from the Company or shareholders (with over 5% shares held) in or
occurred in the previous period but continued to reporting period
√Applicable □Not applicable
Type of
Commitment Commitment Implementatio
Commitments Promise commitment Content of commitments
date term n
s
Commitments for
Share Merger
Reform
As a large pharmaceutical
commercial enterprise whose
business involves pharmaceutical
wholesale and retail, Sinopharm
Holding may overlap with the
Company in geographical
segmentation during its future
business development. To avoid
the potential peer competition
brought by such geographical
Commitments in
Commitmen overlap, Sinopharm Holding Normally
report of Sinopharm Long-term
t of undertakes that, upon the transfer 2005-06-21 implement
acquisition or equity Holding effective
shareholders of shares of Sinopharm Holding
change
Guangzhou it held to Accord
Pharma, “1. it will not
newly-establish or broaden within
Guangdong any business
operation that actually compete
with that of Accord Pharma, or
set up any new subsidiaries or
subordinate enterprises who
engage in such business. 2. It will
enter into business delineation
9
国药集团一致药业股份有限公司 2016 年第一季度报告全文
with Accord Pharma and
Sinopharm Holding Guangzhou,
thereby giving the three parties
clear geographical areas to carry
out pharmaceutical wholesale and
retail businesses, so as to avoid
potential peer competition. Apart
from above, Sinopharm Holding
will no longer newly-establish
any enterprise that may compete
with Accord Pharma in the
production and R&D of
pharmaceutical products.”
Commitments in
assets reorganization
Sinopharm Holding has
undertaken in the Letter of
Undertaking from Sinopharm
Group Co. Ltd. on Avoiding Peer
Competition that, “I. the
Company and the enterprises it
wholly-owns, controls or has de
facto control over (excluding Controlling
Sinopharm Accord and its shareholder
controlled enterprises, similarly is implement
hereinafter) do not exist any in real
business or operation that would earnest,
constitute substantive peer Sinopharm
Commitments make
Commitmen competition with Sinopharm Accord will
in initial public Sinopharm Long-term
t of Accord and its controlled 2013-09-05 actively urged
offering or Holding effective
shareholders enterprises. II. the Company and the
re-financing
the enterprises it wholly-owns, controlling
controls or has de facto control shareholder
over will not engage in, and actual
participate in or carry out in controller to
Guangdong and Guangxi any fulfill
business or activities that would commitments
constitute substantive competition
with the pharmaceutical
commercial businesses of
Sinopharm Accord. III. The
Company and the enterprises it
wholly-owns, controls or has de
facto control over will not engage
10
国药集团一致药业股份有限公司 2016 年第一季度报告全文
in, participate in or carry out any
business or activities that would
constitute substantive competition
with the pharmaceutical industrial
businesses of Sinopharm Accord.
IV. The Company will not make
use of its control over Sinopharm
Accord to damage the legal
interests of Sinopharm Accord
and other shareholders (especially
minority shareholders). The
Letter of Undertaking takes effect
since the date of issue and will
remain effective during the entire
period when the Company has
been the controlling shareholder
or connected party of Sinopharm
Accord. During the validity of the
Undertaking, the Company will
indemnify in time Sinopharm
Accord from any loss which may
arise out of the Company’s
violation of the Undertaking.”
Sinopharm Holding has
undertaken in the Letter of
Undertaking from Sinopharm
Group Co. Ltd. on Controlling
Standardization of the Connected shareholder
Transactions with China National is implement
Accord Medicines Corporation in real
Ltd. that, “I. during the period earnest,
when the Company takes control Sinopharm
Commitmen over Sinopharm Accord, the Accord will
Sinopharm Long-term
t of Company and the companies or 2013-09-05 actively urged
Holding effective
shareholders enterprises it directly or indirectly the
controls (hereinafter referred to as controlling
“Connected Party”) will strictly shareholder
standardize the connected and actual
transactions with Sinopharm controller to
Accord and its controlled fulfill
enterprises. II. for those commitments
connected transactions beyond
avoidance or out of reasonable
causes, the Company and
11
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Connected Party will enter into
standardized connected
transaction agreement with
Sinopharm Accord according to
law. Sinopharm Accord will
perform approval procedure
according to relevant laws, rules
and regulations, other
standardization documents and its
constitutional documents, and
fulfill its obligation to disclose
information on connected
transactions. III. For those
connected transactions beyond
avoidance or out of reasonable
causes, the Company and
Connected Party will determine
the prices of connected
transactions based on the prices
of same or similar transactions
entered into by independent third
parties of no connection while
following the principles of open,
fair and just to ensure the
fairness. IV. when the board or
shareholders’ meeting of
Sinopharm Accord votes on the
relevant connected transactions
involving the Company and other
enterprises it controls, the
Company will perform
obligations including that
necessary interested directors and
shareholders shall be abstained
from voting according to relevant
regulations, and follow the legal
procedures for approval of
connected transactions and fulfill
its information disclosure
obligation. V. the Company
guarantees to attend shareholders’
meeting according to the
constitutional documents of
Sinopharm Accord, exercise its
12
国药集团一致药业股份有限公司 2016 年第一季度报告全文
corresponding rights and assumed
its corresponding obligations in
an equitable manner, not to take
advantage of its standing as
controlling shareholder to seek
unjust interests, or to use
connected transactions to illegally
transfer capital or profit out of
Sinopharm Accord, or to
prejudice the legal interests of
Sinopharm Accord and other
shareholders (especially minority
shareholders). VI. The Letter of
Undertaking takes effect since the
date of issue and will remain
effective during the entire period
when the Company has been the
controlling shareholder or
connected party of Sinopharm
Accord. During the validity of the
Undertaking, the Company will
indemnify in time Sinopharm
Accord from any loss that may
arise out of the Company’s
violation of the Undertaking.”
”Sinopharm Group has
undertaken in the Letter of
Undertaking from China National Controlling
Pharmaceutical Group shareholder
Corporation on Avoiding the Peer is implement
Competition with China National in real
Accord Medicines Corporation earnest,
Ltd. that, “I. in the coming five Sinopharm
Commitmen years, Sinopharm Group intends Accord will
Sinopharm Long-term
t of actual to take appropriate measures 2013-10-16 actively urged
Group effective
controller including replacement or the
acquisition of assets or equity controlling
reorganization to solve the shareholder
problem of peer competition and actual
between Weiqida and Sinopharm controller to
Accord. II. apart from the fulfill
matters disclosed in the past and commitments
in the Letter of Undertaking, the
Company and the enterprises it
13
国药集团一致药业股份有限公司 2016 年第一季度报告全文
wholly-owns, controls or has de
facto control over (excluding
Sinopharm Accord and its
controlled enterprises, similarly
hereinafter) do not directly
engage in, participate in or carry
out within the PRC any business
or activities that would constitute
substantive competition with the
production and operation of
Sinopharm Accord. The relative
undertakings in respect of
avoiding peer competition given
by the Company in the past
remain valid. III. The Company
will not take advantage of its
control over Sinopharm Accord to
damage the legal interests of
Sinopharm Accord and other
shareholders (especially minority
shareholders). IV. The Letter of
Undertaking takes effect since the
date of issue and will remain
effective during the entire period
when the Company has been the
de facto controller or connected
party of Sinopharm Accord.”
Sinopharm Group has undertaken
in the Letter of Undertaking from Controlling
China National Pharmaceutical shareholder
Group Corporation on is implement
Standardization of the Connected in real
Transactions with China National earnest,
Accord Medicines Corporation Sinopharm
Commitmen Ltd that, “I. during the period Accord will
Sinopharm Long-term
t of actual when the Company takes control 2013-09-22 actively urged
Group effective
controller over Sinopharm Accord, the the
Company and the companies or controlling
enterprises it directly or indirectly shareholder
controls (hereinafter referred to as and actual
“Connected Party”) will strictly controller to
standardize the connected fulfill
transactions with Sinopharm commitments
Accord and its controlled
14
国药集团一致药业股份有限公司 2016 年第一季度报告全文
enterprises. II. for those
connected transactions beyond
avoidance or out of reasonable
causes, the Company and
Connected Party will enter into
standardized connected
transaction agreement with
Sinopharm Accord according to
law. Sinopharm Accord will
perform approval procedure
according to relevant laws, rules
and regulations, other
standardization documents and its
constitutional documents, and
fulfill its obligation to disclose
information on connected
transactions. III. For those
connected transactions beyond
avoidance or out of reasonable
causes, the Company and
Connected Party will determine
the prices of connected
transactions based on the prices
of same or similar transactions
entered into by independent third
parties of no connection while
following the principles of open,
fair and just to ensure the
fairness. IV. when the board or
shareholders’ meeting of
Sinopharm Accord votes on the
relevant connected transactions
involving the Company and other
enterprises it controls, the
Company will perform
obligations including that
necessary interested directors and
shareholders shall be abstained
from voting according to relevant
regulations, and follow the legal
procedures for approval of
connected transactions and fulfill
its information disclosure
obligation. V. the Company
15
国药集团一致药业股份有限公司 2016 年第一季度报告全文
guarantees not to take advantage
of its standing as actual controller
to seek unjust interests, or to use
connected transactions to illegally
transfer capital or profit out of
Sinopharm Accord, or to
prejudice the legal interests of
Sinopharm Accord and other
shareholders (especially minority
shareholders).”VI. The Letter of
Undertaking takes effect since the
date of issue and will remain
effective during the entire period
when the Company has been the
actual controller or connected
party of Sinopharm Accord.
Equity incentive
commitment
Other commitments
for medium and
small shareholders
Completed on time
Yes
or not
IV. Predict of the business performance from January to June 2016
Warnings and reasons of the predict that the cumulative net profit from the begin of the year to the end of next report period may be
loss or have great changes comparing with the same period of last year
□Applicable √Not applicable
V. Securities Investment
□ Applicable √ Not applicable
No security investment in the Period.
VI. Derivative investment
□ Applicable √ Not applicable
No derivative investment in the Period.
VII. Registration form for receiving research, communication and interview in the report period
√Applicable □ Not applicable
Date Method Type of investors Basic situation index of investigation
Research situation see “Investor relations
2016-01-13 Field research Institute activity record on 13 January 2016” that
the Company uploaded to Shenzhen
16
国药集团一致药业股份有限公司 2016 年第一季度报告全文
stock exchange interactions
(http://irm.cninfo.com.cn/ssessgs/S0000
28/index.html)
VIII. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the period.
IX. Non-operational fund occupation from controlling shareholders and its related party
□ Applicable √ Not applicable
The Company had no non-operational fund occupation form controlling shareholders and its related party in the period.
17
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2016-03-31
In RMB
Item Balance at period-end Balance at period-begin
Current assets:
Monetary funds 1,476,829,805.83 1,570,706,970.51
Settlement provisions
Capital lent
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial assets
Notes receivable 827,173,710.53 820,125,807.67
Accounts receivable 7,516,654,933.29 6,153,830,882.75
Accounts paid in advance 59,788,518.91 72,041,261.84
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Interest receivable
Dividend receivable
Other receivables 46,197,363.97 38,175,884.46
Purchase restituted finance asset
Inventories 2,241,114,541.67 2,533,160,758.28
Divided into assets held for sale 2,456,876.83
Non-current asset due within one
year
Other current assets 12,350,715.19 19,456,915.58
Total current assets 12,180,109,589.39 11,209,955,357.92
Non-current assets:
18
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Loans and payments on behalf
Finance asset available for sales
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 190,892,496.96 180,831,714.55
Investment property 142,669,542.33 145,102,318.77
Fixed assets 1,098,019,776.18 1,079,412,437.53
Construction in progress 142,266,655.14 176,096,786.58
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 136,860,507.21 137,720,156.55
Expense on Research and
5,619,315.47 5,619,315.47
Development
Goodwill 79,378,833.15 79,378,833.15
Long-term expenses to be
38,791,881.83 40,464,563.93
apportioned
Deferred income tax asset 84,499,424.29 88,210,062.44
Other non-current asset 73,220,793.01 75,558,188.42
Total non-current asset 1,992,219,225.57 2,008,394,377.39
Total assets 14,172,328,814.96 13,218,349,735.31
Current liabilities:
Short-term loans 1,327,167,887.16 1,212,959,267.74
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 1,159,255,532.51 1,301,594,416.81
Accounts payable 4,744,168,373.49 4,036,910,159.14
Accounts received in advance 53,354,398.79 56,943,167.40
Selling financial asset of
repurchase
Commission charge and
19
国药集团一致药业股份有限公司 2016 年第一季度报告全文
commission payable
Wage payable 96,127,182.14 164,315,934.17
Taxes payable 112,615,669.79 72,863,480.20
Interest payable 6,111,460.23 6,544,067.19
Dividend payable
Other accounts payable 576,015,459.88 468,450,153.85
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Divided into liability held for sale
Non-current liabilities due within 1
7,520,033.19 5,444,858.84
year
Other current liabilities
Total current liabilities 8,082,335,997.18 7,326,025,505.34
Non-current liabilities:
Long-term loans 72,495,172.30 72,495,172.30
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable 9,327,331.42 8,394,559.05
Long-term wages payable 2,549,520.00 2,499,100.00
Special accounts payable 1,287,000.00 1,287,000.00
Accrual liabilities
Deferred income 164,314,411.13 173,099,023.98
Deferred income tax liabilities 23,119,723.98 22,647,074.06
Other non-current liabilities 45,427,343.31 45,427,343.31
Total non-current liabilities 318,520,502.14 325,849,272.70
Total liabilities 8,400,856,499.32 7,651,874,778.04
Owner’s equity:
Share capital 362,631,943.00 362,631,943.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
20
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Capital public reserve 1,863,894,533.34 1,863,894,533.34
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus public reserve 181,315,971.50 181,315,971.50
Provision of general risk
Retained profit 3,244,540,132.49 3,045,551,246.71
Total owner’s equity attributable to
5,652,382,580.33 5,453,393,694.55
parent company
Minority interests 119,089,735.31 113,081,262.72
Total owner’s equity 5,771,472,315.64 5,566,474,957.27
Total liabilities and owner’s equity 14,172,328,814.96 13,218,349,735.31
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item Closing balance Opening balance
Current assets:
Monetary funds 435,571,746.30 429,437,078.35
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes receivable 6,797,635.32 43,896,287.87
Accounts receivable 606,415,383.70 381,093,808.53
Account paid in advance 1,789,968.89 5,452,046.55
Interest receivable 1,967,461.71 2,053,659.27
Dividends receivable
Other receivables 1,623,382,771.08 1,613,862,656.17
Inventories 163,105,942.26 182,659,794.51
Divided into assets held for sale
Non-current assets maturing within
one year
Other current assets 39,482.38 39,482.38
Total current assets 2,839,070,391.64 2,658,494,813.63
21
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Non-current assets:
Available-for-sale financial assets
Held-to-maturity investments
Long-term receivables
Long-term equity investments 2,805,291,991.34 2,795,231,208.93
Investment property 4,177,792.46 4,379,786.84
Fixed assets 421,747,206.06 391,937,393.50
Construction in progress 98,147,535.71 129,851,067.29
Project materials
Disposal of fixed assets
Productive biological assets
Oil and natural gas assets
Intangible assets 35,507,533.83 35,678,610.77
Research and development costs
Goodwill
Long-term deferred expenses 7,083,730.42 7,417,691.74
Deferred income tax assets 2,906,189.80 2,906,189.80
Other non-current assets 35,700,861.50 34,856,698.50
Total non-current assets 3,410,562,841.12 3,402,258,647.37
Total assets 6,249,633,232.76 6,060,753,461.00
Current liabilities:
Short-term borrowings 190,000,000.00 106,000,000.00
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 171,340,931.37 285,394,838.22
Accounts payable 440,401,314.96 292,794,309.39
Accounts received in advance 5,361,477.29 5,841,769.74
Wage payable 15,529,796.84 22,441,125.24
Taxes payable 8,441,746.68 10,770,924.28
Interest payable 352,433.94 354,492.17
Dividend payable
Other accounts payable 737,363,557.74 680,741,770.79
22
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Divided into liability held for sale
Non-current liabilities due within 1
year
Other current liabilities
Total current liabilities 1,568,791,258.82 1,404,339,229.83
Non-current liabilities:
Long-term loans 72,495,172.30 72,495,172.30
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable
Long-term wages payable 72,000.00 72,000.00
Special accounts payable 800,000.00 800,000.00
Projected liabilities
Deferred income 4,949,999.98 5,074,999.99
Deferred income tax liabilities 3,773,319.00 3,773,319.00
Other non-current liabilities
Total non-current liabilities 82,090,491.28 82,215,491.29
Total liabilities 1,650,881,750.10 1,486,554,721.12
Owners’ equity:
Share capita 362,631,943.00 362,631,943.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
Capital public reserve 1,869,692,921.70 1,869,692,921.70
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus reserve 181,315,971.50 181,315,971.50
Retained profit 2,185,110,646.46 2,160,557,903.68
Total owner’s equity 4,598,751,482.66 4,574,198,739.88
Total liabilities and owner’s equity 6,249,633,232.76 6,060,753,461.00
23
国药集团一致药业股份有限公司 2016 年第一季度报告全文
3. Consolidated Profit Statement
In RMB
Item Current Period Last Period
I. Total operating income 7,053,846,519.17 6,261,714,700.23
Including: Operating income 7,053,846,519.17 6,261,714,700.23
Interest income
Insurance gained
Commission charge and commission
income
II. Total operating cost 6,808,388,675.34 6,022,798,273.95
Including: Operating cost 6,519,978,864.87 5,727,401,760.21
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 14,380,933.14 13,110,911.30
Sales expenses 145,882,059.43 149,553,656.91
Administration expenses 103,771,187.01 101,713,713.18
Financial expenses 21,233,905.22 27,144,103.26
Losses of devaluation of asset 3,141,725.67 3,874,129.09
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed
10,060,782.41 12,709,847.11
with “-”)
Including: Investment income on
10,060,782.41 12,709,847.11
affiliated company and joint venture
Exchange income (Loss is listed
with “-”)
III. Operating profit (Loss is listed with
255,518,626.24 251,626,273.39
“-”)
24
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Add: Non-operating income 6,777,356.51 5,960,690.37
Including: Disposal gains of
1,484,859.51 2,827.43
non-current asset
Less: Non-operating expense 172,206.34 323,927.54
Including: Disposal loss of
34,377.22 121,498.58
non-current asset
IV. Total Profit (Loss is listed with “-”) 262,123,776.41 257,263,036.22
Less: Income tax expense 57,126,418.04 55,141,543.92
V. Net profit (Net loss is listed with “-”) 204,997,358.37 202,121,492.30
Net profit attributable to owner’s of
199,027,472.31 197,026,237.82
parent company
Minority shareholders’ gains and
5,969,886.06 5,095,254.48
losses
VI. Net after-tax of other comprehensive
income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of
re-measurement of net defined benefit
plan liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method which
will not be reclassified subsequently to
profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method which
will be reclassified subsequently to profit
or loss
2. Gains or losses arising
from changes in fair value of
available-for-sale financial assets
25
国药集团一致药业股份有限公司 2016 年第一季度报告全文
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale financial
assets
4. The effect hedging portion
of gains or losses arising from cash flow
hedging instruments
5. Translation differences
arising on translation of foreign currency
financial statements
6. Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 204,997,358.37 202,121,492.30
Total comprehensive income
199,027,472.31 197,026,237.82
attributable to owners of parent Company
Total comprehensive income
5,969,886.06 5,095,254.48
attributable to minority shareholders
VIII. Earnings per share:
(i) Basic earnings per share 0.549 0.543
(ii) Diluted earnings per share 0.549 0.543
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Wang Ying
4. Profit Statement of Parent Company
In RMB
Item Current Period Last Period
I. Operating income 749,904,714.81 682,110,778.60
Less: Operating cost 722,509,130.22 651,556,733.03
Operating tax and extras 1,619,254.47 1,291,426.07
Sales expenses 10,022,247.07 11,197,849.92
Administration expenses 11,851,048.63 10,188,227.73
Financial expenses -15,476,187.80 -15,344,108.10
Losses of devaluation of asset 181,694.80 142,228.63
Add: Changing income of fair
value(Loss is listed with “-”)
26
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Investment income (Loss is
10,060,782.41 12,709,847.11
listed with “-”)
Including: Investment income
10,060,782.41 12,709,847.11
on affiliated company and joint venture
II. Operating profit (Loss is listed
29,258,309.83 35,788,268.43
with “-”)
Add: Non-operating income 125,086.40 2.62
Including: Disposal gains of
non-current asset
Less: Non-operating expense 0.01
Including: Disposal loss of
non-current asset
III. Total Profit (Loss is listed with
29,383,396.23 35,788,271.04
“-”)
Less: Income tax expense 4,830,653.45 5,769,605.99
IV. Net profit (Net loss is listed with
24,552,742.78 30,018,665.05
“-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of
re-measurement of net defined benefit
plan liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method
which will not be reclassified
subsequently to profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method
which will be reclassified subsequently
to profit or loss
2. Gains or losses arising
from changes in fair value of
27
国药集团一致药业股份有限公司 2016 年第一季度报告全文
available-for-sale financial assets
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale
financial assets
4. The effect hedging
portion of gains or losses arising from
cash flow hedging instruments
5. Translation differences
arising on translation of foreign
currency financial statements
6. Other
VI. Total comprehensive income 24,552,742.78 30,018,665.05
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Cash Flow Statement
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 6,388,288,249.42 6,225,835,431.92
services
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings and
investment
Net increase of amount from
disposal financial assets that measured
28
国药集团一致药业股份有限公司 2016 年第一季度报告全文
by fair value and with variation
reckoned into current gains/losses
Cash received from interest,
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Write-back of tax received 4,086,750.89 333,471.38
Other cash received concerning
23,407,284.10 29,217,661.76
operating activities
Subtotal of cash inflow arising from
6,415,782,284.41 6,255,386,565.06
operating activities
Cash paid for purchasing
commodities and receiving labor 6,089,255,619.56 5,644,089,272.34
service
Net increase of customer loans
and advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to/for staff and workers 230,667,038.12 215,442,209.33
Taxes paid 139,883,077.94 132,719,577.58
Other cash paid concerning
56,438,014.78 80,955,899.11
operating activities
Subtotal of cash outflow arising from
6,516,243,750.40 6,073,206,958.36
operating activities
Net cash flows arising from operating
-100,461,465.99 182,179,606.70
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
income
29
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Net cash received from disposal of
fixed, intangible and other long-term 2,149,217.61 22,330.68
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
investing activities
Subtotal of cash inflow from investing
2,149,217.61 22,330.68
activities
Cash paid for purchasing fixed,
31,818,451.80 49,381,727.56
intangible and other long-term assets
Cash paid for investment
Net increase of mortgaged loans
Net cash received from
subsidiaries and other units obtained
Other cash paid concerning
26,754,358.77 252,000.00
investing activities
Subtotal of cash outflow from investing
58,572,810.57 49,633,727.56
activities
Net cash flows arising from investing
-56,423,592.96 -49,611,396.88
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
1,470,000.00
investment
Including: Cash received from
absorbing minority shareholders’ 1,470,000.00
investment by subsidiaries
Cash received from loans 46,309,896.11
Cash received from issuing bonds
Other cash received concerning
112,026,204.05
financing activities
Subtotal of cash inflow from financing
158,336,100.16 1,470,000.00
activities
Cash paid for settling debts 80,100,000.00 63,839,764.78
Cash paid for dividend and profit
19,157,310.80 25,275,601.52
distributing or interest paying
Including: Dividend and profit of
30
国药集团一致药业股份有限公司 2016 年第一季度报告全文
minority shareholder paid by
subsidiaries
Other cash paid concerning
1,082,001.86 29,012,559.76
financing activities
Subtotal of cash outflow from
100,339,312.66 118,127,926.06
financing activities
Net cash flows arising from financing
57,996,787.50 -116,657,926.06
activities
IV. Influence on cash and cash
equivalents due to fluctuation in 9,250.41
exchange rate
V. Net increase of cash and cash
-98,888,271.45 15,919,534.17
equivalents
Add: Balance of cash and cash
1,569,226,304.36 854,212,006.84
equivalents at the period -begin
VI. Balance of cash and cash
1,470,338,032.91 870,131,541.01
equivalents at the period -end
6. Cash Flow Statement of Parent Company
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 649,815,583.17 711,445,698.87
services
Write-back of tax received
Other cash received concerning
7,378,429.80 3,324,178.44
operating activities
Subtotal of cash inflow arising from
657,194,012.97 714,769,877.31
operating activities
Cash paid for purchasing
commodities and receiving labor 660,517,729.80 697,915,966.60
service
Cash paid to/for staff and workers 21,139,613.30 18,182,948.12
Taxes paid 12,632,832.46 6,338,325.38
Other cash paid concerning
3,957,308.12 8,502,230.29
operating activities
31
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Subtotal of cash outflow arising from
698,247,483.68 730,939,470.39
operating activities
Net cash flows arising from operating
-41,053,470.71 -16,169,593.08
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
17,461,541.74 15,334,120.54
income
Net cash received from disposal of
fixed, intangible and other long-term
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
524,540,000.00 735,380,315.47
investing activities
Subtotal of cash inflow from investing
542,001,541.74 750,714,436.01
activities
Cash paid for purchasing fixed,
16,955,491.97 43,164,474.15
intangible and other long-term assets
Cash paid for investment
Net cash received from
subsidiaries and other units
Other cash paid concerning
551,283,252.00 765,721,572.00
investing activities
Subtotal of cash outflow from investing
568,238,743.97 808,886,046.15
activities
Net cash flows arising from investing
-26,237,202.23 -58,171,610.14
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Cash received from loans 80,100,000.00 57,656,125.85
Cash received from issuing bonds
Other cash received concerning
1,356,395,860.16
financing activities
32
国药集团一致药业股份有限公司 2016 年第一季度报告全文
Subtotal of cash inflow from financing
1,436,495,860.16 57,656,125.85
activities
Cash paid for settling debts 80,100,000.00 10,000,000.00
Cash paid for dividend and profit
2,805,513.22 4,011,288.08
distributing or interest paying
Other cash paid concerning
1,280,165,006.05 2,000,160.00
financing activities
Subtotal of cash outflow from
1,363,070,519.27 16,011,448.08
financing activities
Net cash flows arising from financing
73,425,340.89 41,644,677.77
activities
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
6,134,667.95 -32,696,525.45
equivalents
Add: Balance of cash and cash
429,437,078.35 257,173,314.81
equivalents at the period -begin
VI. Balance of cash and cash
435,571,746.30 224,476,789.36
equivalents at the period -end
II. Audit report
Whether the first quarterly report had been audited or not
□ Yes √ No
The first quarterly report of the Company had not been audited.
33
